OPQ Issues Annual Report for 2019
The Office of Pharmaceutical Quality (OPQ) within FDA’s Center for Drug Evaluation and Research has published their 2019 annual report describing accomplishments in 2019 and over the office’s five-year life. OPQ’s accomplishments included efforts in drug assessment, inspection, surveillance, policy, and research. These accomplishments have helped support patient and consumer access to needed medicines. OPQ has a unique role at the U.S. Food and Drug Administration, with activities that impact all human drug user fee programs: new drugs, generics, and biologics – including biosimilars. OPQ has the same expectations for quality for all classes of drugs whether made in the U.S. or abroad. A quality product of any kind consistently meets the expectations of the user. Drugs are no different. Patients expect safe and effective drugs with every dose they take. All drugs marketed in the U.S. must meet quality standards that ensure every dose is safe and effective – and free of contamination and defects. Quality is what gives patients and consumers confidence in their next dose of medicine. Please read OPQ’s Annual Report and join us in a commitment to quality. |
.png)
No hay comentarios:
Publicar un comentario